[go: up one dir, main page]

SV2003001183A - Anticuerpos de interluquina-1 beta ref.x-14900 - Google Patents

Anticuerpos de interluquina-1 beta ref.x-14900

Info

Publication number
SV2003001183A
SV2003001183A SV2002001183A SV2002001183A SV2003001183A SV 2003001183 A SV2003001183 A SV 2003001183A SV 2002001183 A SV2002001183 A SV 2002001183A SV 2002001183 A SV2002001183 A SV 2002001183A SV 2003001183 A SV2003001183 A SV 2003001183A
Authority
SV
El Salvador
Prior art keywords
antibodies
interluquine
beta ref
ref
beta
Prior art date
Application number
SV2002001183A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2003001183A publication Critical patent/SV2003001183A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL PRESENTE INVENTO INCLUYE ANTICUERPOS DE ALTA AFINIDAD QUE NEUTRALIZAN LA ACTIVIDAD DE IL-1B IN VIVO. ESTOS ANTICUERPOS PUEDEN USARSE PARA TRATAR VARIAS ENFERMEDADES TALES COMO LA ARTRITIS REUMATOIDEA Y LA OSTEOARTRITIS.
SV2002001183A 2001-07-26 2002-07-25 Anticuerpos de interluquina-1 beta ref.x-14900 SV2003001183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30797301P 2001-07-26 2001-07-26
US31227801P 2001-08-14 2001-08-14

Publications (1)

Publication Number Publication Date
SV2003001183A true SV2003001183A (es) 2003-07-29

Family

ID=26976031

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001183A SV2003001183A (es) 2001-07-26 2002-07-25 Anticuerpos de interluquina-1 beta ref.x-14900

Country Status (8)

Country Link
US (1) US20050075488A1 (es)
EP (1) EP1423432A4 (es)
JP (1) JP2004536605A (es)
AR (1) AR036189A1 (es)
AU (1) AU2002355249A1 (es)
PE (1) PE20030282A1 (es)
SV (1) SV2003001183A (es)
WO (1) WO2003010282A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003073982A2 (en) * 2002-02-28 2003-09-12 Eli Lilly And Company Anti-interleukin-1 beta analogs
WO2004067568A2 (en) * 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
CA2590164A1 (en) * 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP2314623B1 (en) 2005-06-21 2012-07-04 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
WO2007002362A2 (en) * 2005-06-24 2007-01-04 Duke University A direct drug delivery system based on thermally responsive biopolymers
AU2006306280B2 (en) * 2005-10-26 2010-06-17 Novartis Ag Novel use of IL-1beta compounds
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CN103405768A (zh) * 2006-12-20 2013-11-27 爱克索马技术有限公司 用于治疗IL-1β相关疾病的方法
CA2839162A1 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Methods for the treatment of il-1-.beta. related diseases
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
HRP20130042T1 (hr) * 2008-06-06 2013-03-31 Xoma Technology Ltd. Postupci lijeäśenja reumatoidnog artritisa
WO2010028273A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
CA2797846A1 (en) 2010-05-07 2011-11-10 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related conditions
US20110307788A1 (en) * 2010-06-15 2011-12-15 Microsoft Corporation Role-based presentation views
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
US10436795B2 (en) * 2016-09-16 2019-10-08 Institute For Cancer Research Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20020157130A1 (en) 1999-03-12 2002-10-24 Ry Wagner Trait-associated gene identification method

Also Published As

Publication number Publication date
WO2003010282A3 (en) 2004-02-12
PE20030282A1 (es) 2003-03-25
EP1423432A2 (en) 2004-06-02
AR036189A1 (es) 2004-08-18
WO2003010282A2 (en) 2003-02-06
AU2002355249A1 (en) 2003-02-17
JP2004536605A (ja) 2004-12-09
US20050075488A1 (en) 2005-04-07
EP1423432A4 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
SV2003001183A (es) Anticuerpos de interluquina-1 beta ref.x-14900
BRPI0406565A (pt) Mistura de agente de suporte e método para sua formação
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
BRPI0620946A8 (pt) anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
UY30430A1 (es) Compuestos
ME01486B (me) Novi pirolo [3, 2-d)pirimidin-4-on derivati i njihova primjena u terapiji
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
MX2022012621A (es) Enlazadores de variantes de carga.
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
CR7875A (es) Variantes de inmunoglobina y usos de esto
BR0315689A (pt) Alvo para terapia de dano cognitivo
BRPI0516515A (pt) composições contendo lipase, protease e amilase para o tratamento da insuficiência pancreática
SV2006002513A (es) Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
BRPI0413713A (pt) derivados cìclicos como moduladores da atividade de recpetor de quimiocina
ECSP088751A (es) Anticuerpos contra la il-22 humana y usos para los mismos
EA200970874A1 (ru) Антитела против склеростина
HN1999000083A (es) Compuestos de pirrolo(2,3-d) pirimidina
AR031924A1 (es) Anticuerpos anti-cd28 silenciados y el uso de estos
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
BRPI0406689A (pt) Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
BRPI0810130A8 (pt) Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t

Legal Events

Date Code Title Description
FD Lapse